Range Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Range Financial Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-309	Closed	-$220K	–	201
2024 Q4	$220K	Buy	+309	New	+$259K	0.1%	171
2024 Q3	–	Sell	-262	Closed	-$275K	–	160
2024 Q2	$275K	Buy	262 +24	+10%	+$23.3K	0.14%	146
2024 Q1	$229K	Buy	+238	New	+$226K	0.12%	156
2023 Q1	–	Sell	-287	Closed	-$207K	–	182
2022 Q4	$207K	Buy	+287	New	+$212K	0.14%	159
2022 Q2	–	Sell	-369	Closed	-$258K	–	175
2022 Q1	$258K	Sell	369 -23	-6%	-$14.6K	0.16%	145
2021 Q4	$248K	Sell	392 -29	-7%	-$17.8K	0.16%	147
2021 Q3	$255K	Buy	421 +9	+2%	+$5.59K	0.18%	139
2021 Q2	$230K	Buy	+412	New	+$209K	0.17%	147

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Range Financial Group's REGN Position: Q1 2025 in Review

Range Financial Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 309 shares — an estimated $220K sold.

Range Financial Group first reported a position in REGN in Q2 2021 and held it in 8 quarters. The position peaked at $275K in Q2 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Range Financial Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Range Financial Group sold 309 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $220K.
Range Financial Group first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 8 quarters.
Range Financial Group's Regeneron Pharmaceuticals position peaked at $275K in Q2 2024.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Range Financial Group's 13F filing for Q1 2025, filed 14 Apr 2025.